ClinicalTrials.gg
RecruitingNCT06159608Updated Dec 15, 2025

Sex Differences in the Vascular Effects of E-cigarette Use

An Early Phase 1 interventional study of Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor) and Chronic estrogen exposure in E-cigarette Use, sponsored by Anna Stanhewicz, PhD. Recruiting at 1 site in United States. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Anna Stanhewicz, PhD · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 288 studies in Vaping with a site in United States — 66 open to participants now, 74 under way, 1 of them phase 3. Vaping · United States.

Planned enrollment
119th of 258
80 · median 71
Started
2023
with 28 others
Phase 1
16 of 288
7 open now
Primary completion
2026-12
later than 14 of 73 live
Registered
205th of 288
by date

Among the 288 studies in Vaping with a site in United States, this one is the 119th largest by planned enrollment of the 258 interventional ones that give a count, is one of 29 that started in 2023, is one of 16 in phase 1, reaches primary completion later than 14 of the 73 other live ones, and was the 205th registered.

Vaping

404 studies on the registry are indexed under Vaping; 97 are open to participants now.

Browse Vaping studies →

Open to participants now

66 of the 288 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 24 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 288 studies in Vaping with a site in United States, or all of them as a file.
02

Study summary

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored.

In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a dime-sized area of the skin in otherwise healthy young (18-24yrs) chronic e-cigarette users. Local heating of the skin at the microdialysis sites is used to explore differences in mechanisms governing microvascular control. As a compliment to these measurements, we also draw blood from the subjects to measure circulating factors that may contribute to cardiovascular health and examine markers of inflammatory activation. We will also collect urine from female participants to measure estradiol.

03

Conditions studied

  • E-cigarette Use

Browse trials for

04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-24 years old
  • one of the following:

    1. have no history of e-cigarette use
    2. be a current e-cigarette user who has been using e-cigarettes for 6 months or longer

Exclusion criteria

Exclusion Criteria:

  • history of cardiovascular, metabolic, and/or skin diseases
  • >30 kg/m2
  • blood pressure ≥140 systolic and/or ≥ 90 diastolic
  • current or history of tobacco cigarette use
  • current antihypertensive or cholesterol-lowering medication
  • current use of cannabis, marijuana, and/or other illegal substances
  • current use of stimulant drugs
  • currently pregnant or breastfeeding
  • allergy to materials used during the experiment (e.g. latex),
  • known allergy to study drugs
  • healthy control subjects will also be excluded if they have ever used e-cigarettes in the past
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Healthy Young Women

    Young women who do not use e-cigarettes

    Drug: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor) · Other: Chronic estrogen exposure

  • Other
    Healthy Young Men

    Young men who do not use e-cigarettes

    Drug: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)

  • Other
    Young Women using E-cigarettes

    Young women chronically use e-cigarettes

    Drug: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor) · Other: Chronic estrogen exposure

  • Other
    Young Men using E-cigarettes

    Young men chronically use e-cigarettes

    Drug: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)

Interventions

  • DrugLocal heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)

    Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups

  • OtherChronic estrogen exposure

    differences in urine estrogen levels across the menstrual cycle between women groups only

06

What researchers measure

Primary outcomes

  1. Change in microvascular endothelium-dependent dilation response measured by laser-Doppler flowmetry

    cutaneous vascular vasodilator responses to local heating over a microdialysis fiber receiving lactated Ringer's solution, followed by L-NAME infusion to quantify NO-dependent response

    Time frame: at the study visit, an average of 4 hours

  2. monthly estrogen exposure

    daily estradiol levels will be measured in all women for 1 month/menstrual cycle

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 7, 2023
StartActual
Dec 2, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06159608
Lead sponsor
Anna Stanhewicz, PhD
Responsible party
Anna Stanhewicz, PhD (Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Dec 7, 2023
Start date
Dec 2, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 15, 2025

Study contacts

Anna Reid-Stanhewicz, PHD
Contact
anna-stanhewicz@uiowa.edu
319-467-1732

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion